MedTrace Logo

A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL

NCT03467867 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-04-06

No results posted yet for this study

Summary

This is an open-label, multicenter, Phase II study to investigate the efficacy and safety of venetoclax in combination with Rituximab/hyaluronidase human in participants with relapsed or refractory chronic lymphocytic leukemia (CLL).

Conditions

Interventions

DRUG

Venetoclax

Venetoclax will be administered as described in the reporting arm.

DRUG

Rituximab

Rituximab (IV) will be administered as described in the reporting arm.

DRUG

Rituximab/Hyaluronidase Human

Rituximab/Hyaluronidase Human (SC) ill be administered as described in the reporting arm.

Sponsors & Collaborators

  • Hackensack Meridian Health

    collaborator OTHER

  • Georgetown University

    lead OTHER

Principal Investigators

  • Kieron Dunleavy, MD · Georgetown University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-26
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03467867 on ClinicalTrials.gov